Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 881Neoplasms 668Prostatic Neoplasms 455Lung Neoplasms 368Colorectal Neoplasms 335Carcinoma, Non-Small-Cell Lung 320Leukemia, Myeloid, Acute 257Pancreatic Neoplasms 224Brain Neoplasms 210Multiple Myeloma 204Neoplasm Metastasis 201Carcinoma, Hepatocellular 184Head and Neck Neoplasms 183Glioblastoma 170Precursor Cell Lymphoblastic Leukemia-Lymphoma 169Melanoma 159Ovarian Neoplasms 158Squamous Cell Carcinoma of Head and Neck 152Recurrence 139Rectal Neoplasms 137Hematologic Neoplasms 130Sarcoma 126Uterine Cervical Neoplasms 124Stomach Neoplasms 118Carcinoma, Renal Cell 118Triple Negative Breast Neoplasms 116Glioma 116Motor Activity 105Urinary Bladder Neoplasms 100Myelodysplastic Syndromes 99

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Primary Malignant Peripheral Nerve Sheath Tumors × 90 days × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡